
USD
+$0.00
(+0.00%
)At Close (As of Nov 12, 2025)
$36.04M
Market Cap
-
P/E Ratio
-0.46
EPS
$2.45
52 Week High
$0.11
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | - |
| Total Revenue | $0 |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$5.5M |
| Selling General And Administrative | $5.5M |
| Research And Development | - |
| Operating Expenses | $5.5M |
| Investment Income Net | - |
| Net Interest Income | -$357K |
| Interest Income | - |
| Interest Expense | $357K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | - |
| Income Before Tax | -$6.2M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$6.2M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$5.5M |
| Ebitda | -$5.8M |
| Net Income | -$6.2M |
| Field | Value (USD) |
|---|---|
| Total Assets | $2.5M |
| Total Current Assets | $158K |
| Cash And Cash Equivalents At Carrying Value | $64K |
| Cash And Short Term Investments | $64K |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $2.3M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $2.3M |
| Intangible Assets Excluding Goodwill | $2.3M |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $94K |
| Other Non Current Assets | - |
| Total Liabilities | $1.3M |
| Total Current Liabilities | $1.2M |
| Current Accounts Payable | $64K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $272K |
| Total Non Current Liabilities | $24K |
| Capital Lease Obligations | - |
| Long Term Debt | - |
| Current Long Term Debt | $272K |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $272K |
| Other Current Liabilities | $912K |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $1.2M |
| Treasury Stock | - |
| Retained Earnings | -$11M |
| Common Stock | $2.7K |
| Common Stock Shares Outstanding | $19M |
| Field | Value (USD) |
|---|---|
| Gross Profit | - |
| Total Revenue | $0 |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$5.5M |
| Selling General And Administrative | $5.5M |
| Research And Development | - |
| Operating Expenses | $5.5M |
| Investment Income Net | - |
| Net Interest Income | -$357K |
| Interest Income | - |
| Interest Expense | $357K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | - |
| Income Before Tax | -$6.2M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$6.2M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$5.5M |
| Ebitda | -$5.8M |
| Net Income | -$6.2M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Klotho Neurosciences, Inc. is an innovative biopharmaceutical company based in Omaha, Nebraska, committed to developing transformative therapies for neurological and age-related disorders as well as specialty diagnostics. With a strong focus on research excellence and a vision to address significant unmet medical needs, Klotho is poised to revolutionize treatment paradigms within the neurology sector. The company's dedication to pioneering solutions underscores its role as a key player in the biopharmaceutical industry, aiming to enhance patient outcomes through advanced therapeutic interventions.